The D3 trial is open and recruiting fast!

30 Jun, 2022

A new trial opened in May, aiming to find out if children and young people living with HIV can take two anti-HIV medicines instead of three. The trial has already recruited 57 participants in Uganda and Thailand.

People living with HIV have to take medicines for life. Therefore, it is important to ensure that these medicines work well and continue to be safe to take for children and young people living with HIV. New approaches that make these anti-HIV medicines less toxic and easier to take could help improve their quality of life and outcomes.

The D3 trials is testing if a new tablet that contains two anti-HIV medicines (dolutegravir and lamivudine) is safe and as effective as the currently recommended treatment (dolutegravir plus two other medicines).

The study is taking place in five countries, including South Africa, Spain, Thailand, Uganda, and the UK. The trials aims to recruit 370 children and young people living with HIV, aged between 2 and 15 years old, to take part.

Well done to the D3 sites, and all teams and collaborators involved.

D3 is funded by ViiV Healthcare and sponsored by Penta. The trial is coordinated by the MRCCTU at UCL in close collaboration with Penta and PHPT CTU.

 

Find out more about D3 here

View D3 poster here